×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
PAVM – pavmed inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
PAVM
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
12/9
08:11 am
pavm
PAVmed Inc. (NASDAQ: PAVM) had its price target lowered by analysts at Ascendiant Capital Markets from $21.00 to $19.00. They now have a "buy" rating on the stock.
High
Report
PAVmed Inc. (NASDAQ: PAVM) had its price target lowered by analysts at Ascendiant Capital Markets from $21.00 to $19.00. They now have a "buy" rating on the stock.
11/20
07:57 am
pavm
Lucid Diagnostics Submits Clinical Evidence Package to MolDX Seeking Medicare Coverage for EsoGuard® Esophageal DNA Test [Yahoo! Finance]
Neutral
Report
Lucid Diagnostics Submits Clinical Evidence Package to MolDX Seeking Medicare Coverage for EsoGuard® Esophageal DNA Test [Yahoo! Finance]
11/18
08:17 am
pavm
Lucid Diagnostics to Present at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum [Yahoo! Finance]
Medium
Report
Lucid Diagnostics to Present at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum [Yahoo! Finance]
11/15
02:22 am
pavm
PAVmed Inc (PAVM) Q3 2024 Earnings Call Highlights: Record Revenue and Strategic Restructuring [Yahoo! Finance]
Medium
Report
PAVmed Inc (PAVM) Q3 2024 Earnings Call Highlights: Record Revenue and Strategic Restructuring [Yahoo! Finance]
11/14
03:27 pm
pavm
PAVmed Inc. 2024 Q3 - Results - Earnings Call Presentation [Seeking Alpha]
Low
Report
PAVmed Inc. 2024 Q3 - Results - Earnings Call Presentation [Seeking Alpha]
11/14
08:01 am
pavm
PAVmed Provides Business Update and Third Quarter 2024 Financial Results
Medium
Report
PAVmed Provides Business Update and Third Quarter 2024 Financial Results
10/31
08:31 am
pavm
PAVmed to Hold a Business Update Conference Call and Webcast on November 14, 2024
Low
Report
PAVmed to Hold a Business Update Conference Call and Webcast on November 14, 2024
10/15
07:55 am
pavm
Lucid Diagnostics Receives Notice of Allowance for Key Patent Underlying Its EsoGuard Esophageal DNA Test [Yahoo! Finance]
Medium
Report
Lucid Diagnostics Receives Notice of Allowance for Key Patent Underlying Its EsoGuard Esophageal DNA Test [Yahoo! Finance]
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
12/12
05:20 pm
pavm
Form 144 PAVmed Inc. Filed by: Cox James L
Low
Report
Form 144 PAVmed Inc. Filed by: Cox James L
12/9
05:22 pm
pavm
Form 144 PAVmed Inc. Filed by: Cox James L
Medium
Report
Form 144 PAVmed Inc. Filed by: Cox James L
12/6
05:58 pm
pavm
Form 144 PAVmed Inc. Filed by: Cox James L
Medium
Report
Form 144 PAVmed Inc. Filed by: Cox James L
12/6
04:16 pm
pavm
Form DEF 14A PAVmed Inc. For: Dec 06
Medium
Report
Form DEF 14A PAVmed Inc. For: Dec 06
12/5
05:35 pm
pavm
Form 144 PAVmed Inc. Filed by: Cox James L
Medium
Report
Form 144 PAVmed Inc. Filed by: Cox James L
11/29
04:21 pm
pavm
Form 8-K PAVmed Inc. For: Nov 22
High
Report
Form 8-K PAVmed Inc. For: Nov 22
11/21
04:46 pm
pavm
Form PRE 14A PAVmed Inc. For: Nov 21
Low
Report
Form PRE 14A PAVmed Inc. For: Nov 21
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
3/24
PAVmed to Hold Business Update Conference Call on April 9, 2020
19.1%
3/30 Form NT 10-K PAVmed Inc. For: Dec 31 14.5%
4/9 PAVmed Reports Preliminary Fourth Quarter 2019 Financial Results and Provides Business Update 14.2%
2/11 U.S. FDA Grants PAVmed Subsidiary, Lucid Diagnostics, Breakthrough Device Designation for its EsoGuard Esophageal DNA Test 14.2%
4/21 PAVmed Receives FDA 510(k) Clearance for its CarpX™ Minimally Invasive Carpal Tunnel Device 11.5%
6/25 Form 8-K PAVmed Inc. For: Jun 25 10.6%
12/13 PAVmed Provides Update on CarpX™ Clinical Safety Study 9.4%
3/9 Form 8-K PAVmed Inc. For: Mar 09 8.9%
5/22 Form S-8 PAVmed Inc. 7.8%
3/2 PAVmed Subsidiary Lucid Diagnostics Partners with University of Pennsylvania to Evaluate EsoCheck™ in Eosinophilic Esophagitis (EoE) Patients 7.1%
3/30 Form NT 10-K PAVmed Inc. For: Dec 31 14.5%
4/9 PAVmed Reports Preliminary Fourth Quarter 2019 Financial Results and Provides Business Update 14.2%
2/11 U.S. FDA Grants PAVmed Subsidiary, Lucid Diagnostics, Breakthrough Device Designation for its EsoGuard Esophageal DNA Test 14.2%
4/21 PAVmed Receives FDA 510(k) Clearance for its CarpX™ Minimally Invasive Carpal Tunnel Device 11.5%
6/25 Form 8-K PAVmed Inc. For: Jun 25 10.6%
12/13 PAVmed Provides Update on CarpX™ Clinical Safety Study 9.4%
3/9 Form 8-K PAVmed Inc. For: Mar 09 8.9%
5/22 Form S-8 PAVmed Inc. 7.8%
3/2 PAVmed Subsidiary Lucid Diagnostics Partners with University of Pennsylvania to Evaluate EsoCheck™ in Eosinophilic Esophagitis (EoE) Patients 7.1%
TOP News Decliners
1/13
PAVmed Receives Formal Notification of Nasdaq Continued Listing Compliance
-15.5%
11/5 PAVmed Secures Financing up to $14 Million for Advancement of its Lead Products to Commercialization -12.5%
11/7 Form D PAVmed Inc. -10.9%
3/3 PAVmed Inc (NASDAQ: PAVM) was upgraded by analysts at ValuEngine from a "sell" rating to a "hold" rating. -10.2%
2/27 PAVmed Inc (NASDAQ: PAVM) had its "buy" rating re-affirmed by analysts at Maxim Group. They now have a $5.00 price target on the stock. -8.3%
4/18 PAVmed Inc (NASDAQ: PAVM) had its "buy" rating re-affirmed by analysts at Maxim Group. They now have a $5.00 price target on the stock. -7.7%
5/21 PAVmed Reports First Quarter 2019 Financial Results and Provides Business Update -6.8%
6/24 PAVmed Subsidiary Lucid Diagnostics Receives FDA 510(k) Clearance for EsoCheck™ -6.1%
5/1 Form 8-K PAVmed Inc. For: Apr 30 -6.0%
5/8 Form 424B5 PAVmed Inc. -5.9%
11/5 PAVmed Secures Financing up to $14 Million for Advancement of its Lead Products to Commercialization -12.5%
11/7 Form D PAVmed Inc. -10.9%
3/3 PAVmed Inc (NASDAQ: PAVM) was upgraded by analysts at ValuEngine from a "sell" rating to a "hold" rating. -10.2%
2/27 PAVmed Inc (NASDAQ: PAVM) had its "buy" rating re-affirmed by analysts at Maxim Group. They now have a $5.00 price target on the stock. -8.3%
4/18 PAVmed Inc (NASDAQ: PAVM) had its "buy" rating re-affirmed by analysts at Maxim Group. They now have a $5.00 price target on the stock. -7.7%
5/21 PAVmed Reports First Quarter 2019 Financial Results and Provides Business Update -6.8%
6/24 PAVmed Subsidiary Lucid Diagnostics Receives FDA 510(k) Clearance for EsoCheck™ -6.1%
5/1 Form 8-K PAVmed Inc. For: Apr 30 -6.0%
5/8 Form 424B5 PAVmed Inc. -5.9%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: